Abstract Breast cancer is the leading cause of cancer deaths in women. Diet and lifestyle are major contributing factors to increased breast cancer risk. While mechanisms underlying dietary protection of mammary tumor formation are increasingly elucidated, there remains a dearth of knowledge on the nature and precise actions of specific bioactive components present in foods with purported health effects. The 43-amino acid peptide lunasin (LUN) is found in soybeans, is bioavailable similar to the isoflavone genistein (GEN), and thus may mediate the beneficial effects of soy food consumption. Here, we evaluated whether LUN displays common and distinct actions from those of GEN in non-malignant (mouse HC11) and malignant (human MCF-7) mammary epithelial cells. In MCF-7 cells, LUN up-regulated tumor suppressor phosphatase and tensin homolog deleted in chromosome ten (PTEN) promoter activity, increased PTEN transcript and protein levels and enhanced nuclear PTEN localization, similar to that shown for GEN in mammary epithelial cells. LUN-induced cellular apoptosis, akin to GEN, was mediated by PTEN, but unlike that for GEN, was p53-independent. LUN promoted E-cadherin and b-catenin nonnuclear localization similar to GEN, but unlike GEN, did not influence the proliferative effects of oncogene Wnt1 on HC11 cells. Further, LUN did not recapitulate GEN inhibitory effects on expansion of the cancer stem-like/ progenitor population in MCF-7 cells. Results suggest the concerted actions of GEN and LUN on cellular apoptosis for potential mammary tumor preventive effects and highlight whole food consumption rather than intake of specific dietary supplements with limited biological effects for greater health benefits.
Introduction
Diet and lifestyle are major contributing factors to increased breast cancer risk in the US, currently estimated at 1 in 8 women over the course of her lifetime (Siegel et al. 2012) . Epidemiological studies have shown that only 5-10 % of breast cancers can be linked to heritable gene mutations (Lichtenstein et al. 2000) ; approximately 85 % of breast cancers occur in women with no family history of the disease (Colditz et al. 2012) , and obese, postmenopausal women are more predisposed to developing breast cancer when compared to lean women (Rose and VonaDavis 2010; Ligibel 2011) . On the basis of data obtained from these analyses, many experimental and clinical investigations have been conducted to mechanistically evaluate the linkages of dietary effects, dietary preferences, and amounts of food intake to breast cancer risk (Key et al. 2011; Shikany et al. 2011; Irwin et al. 2011; Boggs et al. 2010) . Such studies are particularly relevant to breast cancer prevention and therapy since the understanding of diet-associated mechanisms that limit the initiation and propagation of cells with tumorigenic potential is requisite to improving breast health in unaffected women and outcome in breast cancer patients.
Over the past several years, we and others have achieved important insights into mechanisms underlying mammary tumor protection by dietary factors in rodent models and established cell lines. Bioactive components present in soy foods, specifically the soy isoflavone genistein (GEN) have been a focus of our studies given the many health benefits attributed to dietary soy intake (Dong and Qin 2011; Jin and MacDonald 2002; Chiesa et al. 2008; Caan et al. 2011; Shu et al. 2009 ). These beneficial effects are considered to be particularly manifest in the lower risk of breast cancer reported for Asian women who consume soy-based foods as part of their regular diets beginning in early life (Korde et al. 2009; Dong and Qin 2011) . We Dave et al. 2005; Su and Simmen 2009; Simmen 2010, 2011; Montales et al. 2012 ) and others (Ullah et al. 2011; Anastasius et al. 2009; Kazi et al. 2003; Vinall et al. 2007 ) have shown that specific bioactive components of soy foods function by regulating cellular networks and pathways that promote apoptosis, inhibit proliferation, induce differentiation, and suppress inflammation, to collectively hinder tumor development and growth.
Soy foods contain bioactive components other than GEN that have been linked to cancer protection (Boué et al. 2009; Wang et al. 2008; Zhou et al. 2002) . Lunasin (LUN) is a 43-amino acid peptide component of post-translationally processed 2S albumin, initially identified in soybeans (Galvez and de Lumen 1999) and also present in barley, wheat and other seeds (Jeong et al. 2007 (Jeong et al. , 2010 Silva-Sanchez et al. 2008) . The anti-carcinogenic properties of LUN have been demonstrated in rodent models of skin (Galvez et al. 2001) and breast (Hsieh et al. 2010a, b) cancers and in colon and breast cancer cell lines Hsieh et al. 2010c; Dia and Gonzalez de Mejia 2011) . Thus far, it is not known how LUN measures up to GEN as a dietary factor with anti-cancer preventative activities. The present study examines LUN effects on mammary epithelial cells, in the context of the functional pathways previously described to be GEN-regulated. We report here that LUN exhibits some but not all of the biological activities attributed to GEN in malignant (MCF-7) and non-malignant (HC11) mammary epithelial cells, which have important implications in mammary tumor protection.
Materials and methods

Animals
Procedures for animal care followed the guidelines approved by the University of Arkansas for Medical Sciences Animal Care and Use Committee. Rats (SpragueDawley; Charles River Laboratories, Wilmington, MA, USA) were housed in polycarbonate cages under conditions of 24°C, 40 % humidity, and a 12-h light-dark cycle with ad libitum access to food and water. Dams during pregnancy and lactation were assigned to one of two semipurified, isocaloric diets made according to the AIN-93G formulation (Reeves et al. 1993) , with corn oil substituting for soybean oil and containing as sole protein source either casein (CAS; New Zealand Milk Products, Santa Rosa, CA, USA) or soy protein isolate (SPI; Solae Company, St Louis, MO). SPI contains 394 ± 16 mg total isoflavones/ kg diet, including genistein (216 ± 2 mg/kg) and daidzein (160 ± 6 mg/kg), both expressed as aglycone equivalents ) and lunasin (38 ± 4 mg/g extracted protein) (De Mejia et al. 2004) . Pups from dams of the same diet groups were pooled at delivery and randomly assigned to dams for suckling (10 pups/dam; 5 males and 5 females). Female pups were weaned at postnatal day (PND) 21 to the same diets as their dams and continued on these diets until PND 50, when sera were collected. Male pups were used in unrelated studies.
Cell culture and treatments
Human MCF-7 mammary carcinoma cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and propagated at 37°C in Minimal Essential Medium (MEM; Sigma-Aldrich, St. Louis, MO, USA) containing 10 % fetal bovine serum (FBS; GIBCO/Invitrogen, Carlsbad, CA, USA) and antibiotic-antimycotic mixture (ABAM; GIBCO/Invitrogen) (Dave et al. 2005) . Prior to treatments, cells were plated at a density of 1 9 10 5 per well in six-well plates, and serum-starved for 18 h in MEM containing 0.5 % charcoal-stripped FBS. Equal volumes of sera were pooled from 6 to 8 PND 50 female rats of the same diet group; pooled sera were used at 1 % final concentration. In studies comparing the effects of genistein (GEN; Sigma-Aldrich, St. Louis, MO, USA) and Lunasin (LUN; American Peptide Co., Sunnyside, CA, USA), cells were treated with GEN (20 nM, 2 lM) dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich); LUN (50 nM, 2 lM) dissolved in PBS-0.1 % DMSO; or vehicle alone (PBS-0.1 % DMSO). The mouse HC11 mammary epithelial cell line was kindly provided by Dr. Jeffrey Rosen (Baylor College of Medicine, Houston, TX, USA). HC11 cells were propagated and treated with recombinant Wnt1 protein (10 ng/ml) (Invitrogen) as previously described (Su and Simmen 2009) 0 ; 150 bp). Mouse primer sequences for C-MYC and 18S were as previously described (Su and Simmen 2009 ). The primers were designed to span introns, using Primer Express (Applied Biosystems, Foster City, CA, USA). Quantitative RT-PCR was performed with the SYBR Green detection system (Applied Biosystems) using an ABI Prism 7000 cycler under previously described conditions (Su and Simmen 2009; Rahal and Simmen 2010) . Relative gene expression was normalized to 18S mRNA.
Immunoprecipitation and immunoblotting
Total cell lysates (RIPA buffer; Sigma-Aldrich), cytoplasmic extracts, and nuclear fractions (NE-PER; Pierce Biotechnology, Rockford, IL, USA) were prepared following the manufacturer's instructions. Protein concentrations were quantified by bicinchoninic acid assay (BioRad) using BSA as standard. Immunoprecipitation followed by Western blotting or Western blotting without immunoprecipitation were performed as previously described (Su and Simmen 2009; Rahal and Simmen 2010) . Primary antibodies used were as follows: PTEN (Cell Signaling Technology, Danvers, CA, USA); p53 (Cell Signaling Technology); b-catenin (Cell Signaling Technology); E-cadherin (BD Transduction Laboratory, San Jose, CA, USA); Lamin A (Sigma-Aldrich); Lamin B1 (Abcam, Cambridge, MA, USA); and a-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Immunoreactive proteins were detected using horseradish peroxidase-linked anti-rabbit secondary antibody (Bio-Rad Laboratories) and enhanced chemiluminescence using Amersham ECL Plus (GE Healthcare Life Sciences, Piscataway, NJ, USA). Densitometric values of immunoreactive bands were quantified using GE ImageScanner III detection system (GE Healthcare Life Sciences) and Quantity One Software (Bio-Rad).
Transient transfection and luciferase assay
The PTEN-luciferase (PTEN-Luc) reporter construct, human PTEN in pGL3basic vector, was a generous gift from Dr. Eileen D. Adamson (The Burnham Institute, La Jolla, CA, USA) (Virolle et al. 2001) . MCF-7 cells (1 9 10 4 per well) were plated into 24-well plates and serum-starved overnight in 0.5 % FBS/MEM. Cells were transfected with PTEN-Luc reporter plasmid or empty vector plasmid (pGL3basic; Promega, Madison, WI, USA) (0.25 lg/well) using Lipofectamine 2000 reagent (Invitrogen) in OPTI-MEM 1 reduced serum-containing medium (Invitrogen). The Renilla Luciferase reporter construct (pRL-SV40; Promega) was co-transfected in all cases as internal control for transfection efficiency. After 6 h, cells were washed with PBS, and the medium was replaced with 0.5 % FBS/MEM. Twenty-four hours later, cells were incubated in fresh medium containing 2 lM LUN or vehicle (PBS) for another 24 h. Luciferase activity in lysates (Lysis Buffer; Promega) was measured using the Dual Luciferase Reagent kit (Promega) and a MLX Microplate Luminometer (Dynex Technologies, Inc., Chantilly, VA, USA). Results were calculated as the ratio of PTEN-Luc to Renilla luciferase activity. Values for relative luciferase activity were obtained from two independent transfection experiments, with each experiment carried out in quadruplicate.
Mammosphere formation assay
The formation of mammospheres by MCF-7 cells followed previously described protocols (Montales et al. 2012) . Plating medium for mammosphere formation consisted of phenol red-free, serum-free Minimal Essential Media (MEM; GIBCO) supplemented with B27 (1X; Invitrogen), 20 ng/ml human basic fibroblast growth factor (Invitrogen), 20 ng/ml human epidermal growth factor (Invitrogen), 10 lg/ml heparin (Sigma-Aldrich), 1 % antibiotic-antimycotic solution (Invitrogen), and 100 lg/ml gentamicin (Sigma-Aldrich). The cells were treated once at initial plating (Passage 1, P1) with vehicle, 2 lM LUN or LUN (2 lM) ? GEN (40 nM). Mammospheres with diameters of C100 lm were manually counted after 5 days using a Zeiss Axiovision microscope (Carl Zeiss). To assess the relative sphere numbers over the second passage (P2), mammospheres from the initial plating (P1) were collected at day 5, dissociated with 0.05 % trypsin (Invitrogen), filtered using a 40 lM sieve, and replated in ultra-lowattachment plates at a density of 5,000 cells per well. Mammosphere formation in P2 was evaluated at day 7 post-plating. Treatment effects were determined from two independent experiments, with quadruplicates performed for each experimental group.
Statistical analysis
At least two independent experiments were conducted for each study, with each experiment performed in triplicate or quadruplicate. Data are presented as mean ± SEM, relative to the control group. Statistical analysis was performed using SigmaStat Software 3.5 (SPSS, Chicago, IL, USA), and significance between treatment groups (P B 0.05) was determined by using two-way analysis of variance (ANOVA) followed by Tukey's post hoc analysis or Student's t test.
Results
Sera from SPI-fed young adult rats increased PTEN expression and enhanced apoptosis of MCF-7 cells
We previously showed that lifetime exposure to dietary SPI increased the apoptotic status of epithelial cells in distinct mammary compartments (Terminal end buds, Lobules, Ductal epithelium) of young adult (PND 50) female rats coincident with these cells' increased expression of tumor suppressor PTEN (Dave et al. 2005) . To evaluate the effects of dietary exposure to SPI relative to CAS on breast cancer cells ex vivo, sera pools from female rats of the two dietary groups (n = 6-8 per group) were added at 1 % final concentration to MCF-7 cells. Treated cells were evaluated after 24 h for apoptotic status (TUNEL, T) and PTEN expression (immunoreactive PTEN, P) by immunofluorescence (Fig. 1a) . Nuclear PTEN ? TUNEL co-localization (D ? T ? P) was further analyzed by dual immunofluorescence. Cells treated with CAS-sera and SPI-sera both showed nuclear-localized TUNEL and PTEN immunostaining (Fig. 1a) , which spatially overlapped. Cells incubated with SPI-sera had a higher percentage of TUNEL-(by threefold) and PTEN (by twofold)-positive cells than corresponding CAS-sera-treated cells (Fig. 1b, c) . Densitometric analyses of PTEN-positive cells indicated higher amounts (by 1.5-fold) of nuclear PTEN with SPI-sera than with CAS-sera treatment (Fig. 1d) .
Lunasin increased PTEN expression and nuclear localization
We previously showed that one mechanism by which the major soy isoflavone genistein (GEN) elicits its antitumor properties is through PTEN pathway activation (Dave et al. 2005; Rahal and Simmen 2010) . To evaluate the possibility that the soy peptide Lunasin (LUN) exerts mammary tumor-inhibitory activities by influencing PTEN expression similar to GEN, MCF-7 cells treated with LUN were evaluated for effects on PTEN transcript and promoter activity, PTEN protein levels, and PTEN nuclear localization, relative to cells treated with vehicle and in some cases, GEN. For these studies, synthetic LUN was used at concentrations (50 nM or 2 lM) higher than its range of detection in sera of humans and rodents exposed to dietary soy (Jeong et al. 2007; Dia et al. 2009 ), since LUN is readily degraded in the absence of Bowman-Birk protease inhibitor (Hsieh et al. 2010c) , and this inhibitor was not included in the culture medium. Synthetic LUN and LUN purified from soybeans were previously demonstrated to exhibit similar bioactivities in L2110 leukemia cells (De Mejia et al. 2010) . GEN, when added, was used at 20 nM and 2 lM, approximating serum levels of occasional and regular soy consumers, respectively (Andrade et al. 2010; Iwasaki et al. 2008) . Treatment with LUN at 2 lM increased PTEN transcript levels and PTEN promoter activity (Fig. 2a, b) . The induction of PTEN gene expression with 2 lM LUN was confirmed at the level of PTEN protein (Fig. 2c) and was accompanied by increased nuclear PTEN localization (Fig. 2d) . Relative to the higher dose, the lower dose of LUN (50 nM) was ineffective in increasing PTEN transcript levels (Fig. 2a) but was modestly effective in inducing PTEN nuclear localization (Fig. 2d) . GEN at the two doses examined, significantly increased PTEN transcript levels ( Fig. 2a) and nuclear localization (Fig. 2d) . While GEN induction of PTEN protein levels was not quantified by Western blotting in the present study, we previously showed that GEN-induced increase in PTEN mRNA levels occurs coincident with the corresponding protein in mammary epithelial cells (Rahal and Simmen 2010) . Moreover, densitometric analyses of nuclear PTEN-staining cells (Fig. 2d) indicated that while GEN increased PTEN protein levels by twofold (20 nM) and fivefold (2 lM), respectively, relative to control cells, LUN induction of PTEN protein levels relative to control cells was 1.5-fold and threefold, respectively, for 50 nM and 2 lM (data not shown).
Lunasin induced apoptosis via PTEN
We previously showed that GEN induction of apoptosis in MCF-7 cells was mediated by PTEN (Dave et al. 2005) . To evaluate whether LUN can induce apoptosis, and if so, whether this activity is mediated by PTEN, LUN-treated MCF-7 cells (2 lM) were examined for apoptotic status by TUNEL, with and without PTEN silencing achieved, respectively, by transfection with PTEN-specific siRNAs or non-targeting siRNAs. LUN increased the percentage of nuclear PTEN-expressing cells (Figs. 2d, 3a) and apoptotic (TUNEL-positive) cells (Fig. 3a, b) . The induction of apoptosis by LUN was highly dose-dependent (50 nM \ 2 lM; P \ 0.001) (Fig. 3b) and was more dramatic (13-fold for 50 nM; 21-fold for 2 lM) than the 2-3-fold induction in nuclear-localized PTEN-positive cells (Fig. 2d ) using the same LUN doses. LUN-induced apoptosis was significantly, but not exclusively inhibited by PTEN knock-down (by [90 % at the transcript level, data not shown); by contrast, knockdown with non-targeting siRNAs had no effect on the apoptotic status of LUNtreated cells (Fig. 3c) . In a previous study (Rahal and Simmen 2010) , we showed that PTEN-mediated induction of apoptosis in the non-malignant human mammary epithelial cell line MCF-10A by GEN involved the contribution of the tumor suppressor p53. Specifically, GEN induction of PTEN was accompanied by increased p53 nuclear localization, and decreased expression of pro-proliferative gene markers. To evaluate whether LUN mediates a similar mechanism, (Fig. 4a) . Similarly, LUN treatment had no significant effects on the transcript levels of p53 and pro-proliferative marker C-MYC and cyclin D1 (CCND1) genes (Fig. 4b) . Further, LUN did not alter the proliferation status of MCF-7 cells as measured by the MTT assay (data not shown).
Lunasin promoted E-cadherin expression and failed to inhibit mammosphere formation
To further define common and distinct pathways between LUN and GEN in mammary epithelial cells, the effects of LUN on two other pathways previously described by our group to be influenced by GEN were evaluated. The first pathway involved GEN up-regulation of E-cadherin expression to attenuate b-catenin signaling in nonmalignant mammary epithelial cells (Su and Simmen 2009) , and the second pathway relates to our recent report of GEN inhibition of mammosphere formation by MCF-7 cells (Montales et al. 2012) . For the first pathway, mouse HC11 mammary epithelial cells were treated with vehicle or LUN (1 lM) for 6 h, and non-nuclear proteins (membrane/cytosolic fractions) were evaluated for levels of E-cadherin and b-catenin by Westerns. Cells treated with LUN showed numerically higher (P = 0.065) E-cadherin and significantly higher (P \ 0.05) b-catenin levels in cytosolic/membrane (non-nuclear) fraction than vehicleonly-treated cells (Fig. 5a ). The increase in b-catenin protein was specific to this cellular fraction, since corresponding nuclear proteins from control and LUN-treated cells did not differ in b-catenin levels (Fig. 5b) . LUN had no effect on C-MYC expression in HC11 cells (Fig. 5c ), recapitulating its absence of effect on C-MYC expression in MCF-7 cells (Fig. 4b) and did not suppress Wnt-1-induced expression of C-MYC (Fig. 5c ). To assess the second pathway, MCF-7 cells were treated at plating with vehicle alone, LUN (2 lM) and LUN (2 lM) ? GEN (40 nM) and evaluated for numbers of mammospheres formed at passage 1 (P1) and passage 2 (P2). LUN did not influence the number of mammosphereforming units in P1 (not shown) and P2 (Fig. 5d) . We have reported recently that GEN at 40 nM significantly reduced mammosphere formation of MCF-7 cells (Montales et al. 2012) . The decrease in mammosphere-forming units by GEN (data not shown) was not affected by LUN (Fig. 5d) .
Discussion
In this study, we sought to determine whether the soybean peptide LUN exerts its breast cancer protective effects via mechanisms similar to those described for the major soy isoflavone GEN. Our results show that LUN exhibits some but not all of the biological activities attributed to GEN in malignant (human MCF-7) and non-malignant (mouse HC11) mammary epithelial cells. These cell lines, while derived from different species, are both estrogen receptor positive, in contrast to the human MCF10A, which is estrogen receptor-negative (Rahal and Simmen 2011) . A shared pathway influenced by LUN and GEN is PTENmediated apoptosis. LUN, similar to GEN, up-regulated PTEN promoter activity, increased PTEN transcript and protein levels, and enhanced nuclear localization of PTEN, leading to induction of the apoptotic status of MCF-7 breast carcinoma cells. The higher apoptotic index induced by LUN was mechanistically linked to LUN-mediated up-regulation of PTEN expression since PTEN siRNA targeting resulted in the dramatic diminution of cellular apoptosis in LUN-treated cells. Another pathway influenced by both LUN and GEN involves the induction of E-cadherin and b-catenin protein levels in non-nuclear (cytosolic/membrane) fractions of mammary epithelial cells. E-cadherin forms a complex with b-catenin outside the nucleus and, in so doing, restricts the migration of b-catenin to the nuclear compartment where it binds the LEF/TCF-1 proteins to induce cellular proliferation via C-MYC activation (Orsulic et al. 1999 ). While we found vehicle-and LUN-treated cells to exhibit comparable levels of nuclear b-catenin and of pro-proliferative marker genes C-MYC and Ccnd1, LUN was ineffective in inhibiting Wnt1-induced cellular proliferation (C-MYC as surrogate marker) in non-malignant HC11 mammary epithelial cells. This differed from previously demonstrated GEN inhibition of Wnt1-induced C-MYC expression (Su and Simmen 2009) of LUN on MCF-7 cell proliferation as measured by MTT assay (data not shown). Also in contrast to GEN, LUN failed to attenuate the expansion of stem cell-like/progenitor cells with tumor initiating potential in MCF-7 cells (Montales et al. 2012; Fillmore and Kuperwasser 2008) . Our collective data, thus, suggest that LUN preferentially promotes apoptotic over inhibiting proliferative pathways in mammary epithelial cells, although this anti-apoptotic activity of LUN is not exclusively PTEN-mediated and may involve other yet-to-be defined mechanisms. These findings are consistent with previous reports showing that LUN stimulated apoptosis in human colon and breast cancer cells Hsieh et al. 2010a ) but had no effect on the growth of numerous immortalized and established cancer lines (Lam et al. 2003) . Our findings that sera from SPI-fed rats significantly influenced PTEN expression, PTEN nuclear localization, and cellular apoptosis, relative to sera from control diet (CAS)-fed mice are consistent with studies reporting the presence of bioactive components such as the isoflavones genistein and daidzein, and LUN in human and rodent sera after dietary soy protein intake (Jeong et al. 2007; Jeong et al. 2010; Dia et al. 2009 ). Based on the reported LUN concentrations of 14 nM in plasma of men after soy consumption (Dia et al. 2009 ) and the potential for degradation of LUN when dissociated from its complex with the Bowman-Birk protease inhibitor (Hsieh et al. 2010a ), the latter a component of soy proteins, we used LUN at higher concentration (50 nM and 1-2 lM) for evaluating its effects on mammary epithelial cells, since these cells were not co-treated with the protease inhibitor. While the higher LUN dose elicited more robust responses than the lower dose and hence was used for all the assays described here, the 50 nM dose was equally effective in inducing nuclear PTEN localization and apoptosis. Given commercial soy products to contain sufficient amounts of LUN (*17 mg of LUN per g of soy protein concentrate) (De Mejia et al. 2004 ) and thus, consumption of 25 g of soybean protein per day will result in a total intake of 0.93 g of LUN (De Mejia et al. 2010) , our results suggest that the mammary tumor preventive effects ascribed to soy protein consumption in many epidemiological studies may be attributed in part, to LUN induction of PTEN-mediated apoptosis of neoplastic mammary epithelial cells.
Our novel finding that LUN can up-regulate PTEN promoter activity leading to increased PTEN mRNA and protein levels raises the question of how LUN may mechanistically activate PTEN transcription. While the mechanisms by which LUN crosses the plasma membrane to enter cells and gets transported to the nucleus remain unclear (Galvez and de Lumen 1999) , nuclear-localized LUN has been shown to bind to deacetylated histones and to inhibit core histones H3 and H4 acetylation (Galvez et al. 2001) , the latter suggesting LUN to function as a histone deacetylase. Numerous studies have shown that promotion of histone acetyl transferase activity, inhibition of histone deacetylase-1 activity, and PTEN acetylation are associated with increased PTEN expression and function (Okomura et al. 2006; Ikenoue et al. 2008; Xiong et al. 2009 ). While counter-intuitive to LUN effects on PTENmediated apoptosis, these findings imply that while LUN may bind to chromatin, its effects on PTEN transcription may not require its direct binding to PTEN gene/promoter regulatory sequences. We have previously shown that GEN up-regulates PTEN transcription by an auto-regulatory loop involving p53 and PTEN; in this mechanism, GEN promotes PTEN-p53 physical association and the recruitment of the PTEN-p53 complex to the p53 binding sites in the PTEN promoter, leading to PTEN transcriptional activation (Rahal and Simmen 2010) . LUN effects are not likely to occur through this mechanism since LUN, distinct from GEN, did not promote p53 localization to the nucleus. Further studies to identify the molecular targets of LUN may shed more light on this subject.
Our findings that GEN and LUN exert common and distinct biological effects may have important implications for mammary tumorigenesis and breast cancer prevention. First, the data highlight the necessity for a balance in nutritional uptake to maintain good health and support the notion that consumption of healthy foods with its diverse bioactive components is more advantageous than intake of high amounts of specific dietary supplements with limited biological effects. Second, since bioactive components function through distinct intermediary molecules that ultimately converge at common signaling pathways, the complete understanding of how these molecules facilitate signaling may lead to the development of drugs that target redundant pathways for increased efficacy. In this regard, while it is known that GEN binds to estrogen receptor-b in mammary epithelial cells to promote ER-b signaling and enhance PTEN expression (Rahal and Simmen 2011) , molecules mediating entry of LUN into nucleus and its binding to chromatin remain unknown. Finally, because cancer cells evolve to survive and, in the process, utilize numerous survival pathways, it is imperative to evaluate the in vivo combinatory effects of identified bioactive components with distinct biological pathways for their utility in breast cancer prevention and therapy.
In summary, our results demonstrate the ability of soybean peptide LUN to induce PTEN-mediated apoptosis of MCF-7 breast cancer cells. This anti-mammary tumor preventive mechanism of LUN recapitulates a major pathway by which the soy isoflavone GEN may also elicit anti-tumor protection. Our findings are highly relevant to understanding the health effects of soy proteins and suggest the potential benefits of the concerted actions of GEN and LUN for developing therapeutic strategies against breast cancer. Additional studies using other available breast cancer cell lines of distinct steroid receptor profiles and invasive properties and existing mouse models of human breast cancer should be conducted to confirm these possibilities.
